29 Jul 2020 12:05
Yourgene Health plc
("Yourgene" or the "Group" or the "Company")
Appointment of Joint Broker
Manchester, UK - 29 July 2020: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces the appointment of Nplus1 Singer Advisory LLP ("N+1 Singer") as joint broker with immediate effect.
Cairn Financial Advisors LLP will continue as the Company's nominated adviser and Stifel Nicolaus Europe Limited will continue as the Company's joint broker.
Yourgene Health plc Lyn Rees, Chief Executive Officer | Tel: +44 (0)161 669 8122 investors@yourgene-health.com | |
Barry Hextall, Chief Financial Officer |
| |
Joanne Cross, Director of Marketing |
| |
|
| |
|
| |
Cairn Financial Advisers LLP (NOMAD) | Tel: +44 (0)20 7213 0880 | |
Liam Murray / James Caithie / Ludovico Lazzaretti | ||
N+1 Singer (Joint Corporate Broker) | Tel: +44 (0)207 496 3000 | |
Aubrey Powell / Tom Salvesen / George Tzimas |
| |
|
| |
Stifel Nicolaus Europe Limited (Joint Corporate Broker) | Tel: +44 (0)20 7710 7600 | |
Nicholas Moore / Matthew Blawat / Ben Maddison |
| |
|
| |
|
| |
Walbrook PR Ltd (Media and Investor Relations) | Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com | |
Paul McManus / Lianne Cawthorne | Mob: 07980 541 893 / Mob: 07584 391 303 | |
|
|
|
About Yourgene Health plc
Yourgene is an international molecular diagnostics group which develops and commercialises genetic products and services. The group works in partnership with global leaders in DNA technology to advance diagnostic science.
Yourgene develops and commercialises simple and accurate molecular diagnostic solutions, for reproductive health and precision medicine. The Group's products include non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, male infertility tests and genetic disease tests. Yourgene's commercial footprint is already established in the UK, Europe, the Middle East, Africa and Asia.
Our product development, research service and commercial capabilities extend across the lifecycle of genetic test development including regulatory submissions. Through our technical expertise and partnerships, Yourgene is also extending its genetic testing offering into oncology.
Yourgene is headquartered in Manchester, UK with offices in Taipei and Singapore, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". For more information, visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.
YGEN.L (YGEN)